Results: The most common grade 3/4 toxic effects in 49 patients were diarrhea (15%) and skin toxic effects (14%). In 48 assessable patients, the overall response rate was 46% and disease control rate was 79%. Median progressionfree survival (PFS) and overall survival (OS) was 9.0 months [95% confidence interval (CI) 7.1-15.6] and 16.5 months (95% CI 11.7-30.1), respectively. Tumor response was more common than nonresponse in epidermal growth factor receptor-expressing tumors (P = 0.041). Tumor PTEN expression was associated with longer PFS (P = 0.035) and OS (P = 0.0127) than no PTEN expression.
introduction
Gastric cancer (GC) is the fourth most common cancer worldwide, with 934 000 new cases per annum. It is a disease with a high death rate (700 000/year) making it the second most common cause of cancer death worldwide [1] . In Europe, the incidence of GC in 2008 was 149 200 cases, although major differences in incidence are apparent according to geographical region [2] .
The typical treatment of patients with advanced GC includes surgery, chemotherapy (CT) and/or radiation therapy. Although GC mortality has declined markedly worldwide, the overall 5-year survival rate for patients with locally advanced disease is <20% and 30% for those who undergo surgery. Many chemotherapeutic agents have shown activity in advanced GC and, currently, cisplatin/ 5-fluorouracil (5-FU)-based chemotherapeutic regimens are the mainstay of treatment of patients with metastatic disease [3] . Oxaliplatin, docetaxel, capecitabine and irinotecan have demonstrated activity in recent phase III trials [4] [5] [6] [7] [8] [9] and increased the armamentarium of treatment options for patients with advanced GC and in the case of irinotecan-based therapy conferred a better quality of life [10] . Additionally, regimens involving the combination of three chemotherapeutic agents have shown promising activity in the treatment of patients with metastatic gastroesophageal cancer (GEC) [4, 5] . However so far, the median survival in all randomized trials remains unsatisfactory, and the identification of less toxic, more effective and convenient regimens is still required.
Even more importantly, the current challenge for patients with GC is the selection and integration of novel targeted agents into new treatment strategies [11] . Very recently, combinations of two cytotoxic drugs with the new HER2 targeted agent (trastuzumab) have been described for highly selected groups of GC patients [12] . The vascular endothelial growth factor (VEGF)-targeted monoclonal antibody bevacizumab in combination with first-line oxaliplatin and docetaxel has demonstrated promising activity in a phase II study of patients with locally advanced or metastatic GC and GEC [13] . In a phase III study, the addition of bevacizumab to first-line capecitabine and cisplatin in patients with advanced GC failed to meet the primary end point [overall survival (OS)], but significant improvements in progression-free survival (PFS) and overall response rates (ORR) were reported [14] . Cetuximab, an immunoglobulin G1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) 1 has demonstrated efficacy in combination with irinotecan-based therapies in patients with metastatic colorectal cancer (mCRC), particularly in patients with KRAS wild-type tumors [15] . Both preclinical and encouraging phase II data suggest a potential benefit of cetuximab especially in combination with conventional cytostatic therapy in patients with advanced GEC [16] [17] [18] .
As both irinotecan/folinic acid (FA)/5-FU (IF) and irinotecan/capecitabine regimens may be effective alternatives to cisplatin-based regimens in the treatment of patients with advanced GEC [7, 9] , we initiated the present phase II Arbeitsgemeinschaft Internistische Onkologie study to evaluate the tolerability and efficacy of cetuximab in combination with IF as first-line treatment of patients with advanced GC or GEC. A concomitantly preplanned analysis of the influence of tumor biomarker status on clinical outcome was also carried out.
patients and methods

study population
Patients were required to have histologically proven adenocarcinoma of the stomach or gastroesophageal junction according to the response evaluation criteria in solid tumors (RECIST) [19] with advanced or metastatic disease, an Eastern Co-operative Oncology Group performance status of 0-2, a life expectancy >12 weeks and adequate hematological, hepatic and renal function and at least 4 weeks since the last surgical procedure. Patients were excluded who had received previous palliative, adjuvant or neoadjuvant CT and/or radiotherapy, prior exposure to monoclonal antibodies, signal transduction inhibitors or EGFR pathway targeting therapies. Additional exclusion criteria included brain or leptomeningeal metastases, any other tumor type (e.g. leiomyosarcoma, lymphoma) or a second cancer except basal skin cell carcinoma or carcinoma in situ of the cervix which had been effectively treated. Also excluded were patients with bowel obstruction, a history of or presence of inflammatory enteropathy or previous extensive intestinal resection (more than hemicolectomy or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, uncontrolled hypercalcemia and known dihydropyrimidine dehydrogenase deficit, other serious disease or other medical conditions and known hypersensitivity to atropine. In addition, concurrent treatment with any other anticancer therapy or chronic systemic immune therapy or hormone therapy not indicated in the study protocol was forbidden. All patients had to provide signed and dated informed consent.
study design and treatment
This open-label nonrandomized phase II study in patients with metastatic GC was conducted at 10 centers in Germany, approved by the appropriate independent ethics committees of the participating sites and designed and conducted according to good clinical practice, the Declaration of Helsinki and all local requirements.
Patients received cetuximab at an initial dose of 400 mg/m 2 
efficacy and safety assessment
The primary objective of this trial was to assess the ORR according to the RECIST criteria [19] . Tumor assessments were carried out at baseline, after 7 weeks and then after every second cycle and at the end of study visit. Secondary objectives included PFS and 1-year survival rate [19] . After the completion of study treatment, patients were followed every 3 months until death or lost to follow-up.
Safety and tolerability of cetuximab in combination with IF was assessed through recording of adverse events (AEs) during the treatment period that were graded according to the National Cancer Institute Common Toxicity Criteria Version 2.0 [20] . In addition, documentation of skin toxicityrelated AE was followed up after the end of study visit until outcome.
biomarker analyses mutational analysis. Mutational analyses of the KRAS, BRAF and PIK3CA genes were carried out. For each tumor sample, DNA was extracted from two deparaffinized 5-lM formalin-fixed paraffin-embedded tumor sections using the High Pure PCR Template Preparation Kit (Roche Diagnostic Spa, Indianapolis, IN), according to the manufacturer's instructions. DNA (25 ng) was amplified using oligonucleotide primers specific for human KRAS (exons 12 and 13), BRAF (V600E) and PIK3CA (exons 9 and 20) genes (supplemental Table 1 protein expression analysis by immunohistochemical staining. Immunohistochemical (IHC) staining of tumor samples was carried out to assess the levels of expression of EGFR1, VEGF-C, VEGF-D, VEGFR3, HER2, SMAD4 and PTEN (supplemental Figure1, available at Annals of Oncology online). IHC staining was carried out as described previously [21] . Paraffin-embedded tissue samples were obtained from 39 patients for all markers except for HER2 and PTEN which, due to limited availability of material, were assessed in 36 and 34 samples, respectively. Three micromolar thick tissue sections were cut and mounted on super frost slides. Tissue slides were deparaffinized, Table 2 , available at Annals of Oncology online). Incubation with secondary antibody (anti-rabbit-mousegoat antibody) was followed by incubation with streptavidin-POD (Dako, Hamburg, Germany). Antibody binding was visualized using DABsolution (Dako, Germany) and the tissues were counterstained by hemalaun solution (Dako, Germany). The staining was evaluated by intensity (0-3) and the extent of the area stained (0-4). These two classifications were added together and divided into the categories negative and positive (weak-moderate-strong). In a further analysis, the groups of patients with only strongly positive staining results were correlated with treatment response. The evaluation of the staining was carried out by two different blinded investigators.
statistical analysis
All data were subjected to descriptive statistical analysis. Continuous data are summarized with at least the following: frequency (n), median, mean, standard deviation (standard error), minimum and maximum. Preplanned analyses were also carried out in subgroups determined by tumor biomarker status and associations with clinical outcome variables were investigated. An exploratory analysis was carried out to investigate the impact of skin rash on OS and tumor response. As skin rash occurs over time, to avoid any potential bias occurring from an analysis of patients with and without rash, a landmark analysis was carried out at fixed time points of 2 months and 1 month. Estimates of survival were calculated from that time point (patients who died before the landmark times were excluded from the analysis).
The proportion of patients showing an overall response to cetuximab and IF was calculated. Study design and confirmatory testing was based on Green and Dahlberg's method for two stage trials [22] . Assuming the planned sample sizes are exactly attained, if the number of responses after completing the first stage with 25 patients was £4, the null hypothesis would not be rejected and the trial would be stopped. If the number of responses after completing the trial was ‡14, then the null hypothesis would be rejected and the combination of cetuximab + IF would be concluded to be promising for further research.
Time-to-event end points including PFS and OS were estimated using Kaplan-Meier methods. Estimates of median values and rates for specific time points were extracted. The primary population for the assessment of efficacy was the full analysis set and AEs were analyzed within the safety analysis set.
results patients
Between August 2006 and September 2007, a total of 49 patients were recruited from 10 centers in Germany. One patient withdrew informed consent before the start of the study and efficacy analysis was carried out in 48 treated patients comprising both the full analysis set and the safety analysis set. Patient characteristics at baseline are summarized in Table 1 . All patients had metastatic adenocarcinoma, 71% had GC, 25% cancer of the gastroesophageal junction and 4% had gastric/ cardia and lower third esophageal adenocarcinoma. Thirteen patients (27%) had received prior surgery.
treatment exposure and safety data
The median number of treatment cycles per patient was 3.0 (1-10) with a median of 2.0 cycles administered as scheduled (0-9). The median number of cycles with study drug reduction was zero (0-3) with a median of zero cycles for reductions of cetuximab (0-3), irinotecan (0-2), 5-FU (0-2) and 5-FA (0-2) reported. Treatment was generally well tolerated, and the incidence of treatment-related grade 3/4 AEs was relatively low (Table 2) . Grades 3/4 AEs were mainly observed for diarrhea (15%), skin toxic effects (8%) and infection (8%). There were no grade 3/4 hematological treatment-related AEs reported, and grade 1/2 treatment-related anemia, neutropenia and leukopenia were reported in <5% of patients. Table 3 ). Furthermore, in 12 tumors displaying strong EGFR expression, the positive association with tumor response was more pronounced (P = 0.006, Table 3 ). In the 13 tumors where EGFR expression was not detectable, only 3 (23%) demonstrated a response. Tumor EGFR expression did not correlate with PFS (log-rank P = 0.567) or OS (log-rank P = 0.663) neither did strong EGFR expression; log-rank P = 0.471 and log-rank P = 0.372 (supplementary Figure 2 , available at Annals of Oncology online). PTEN expression was detected in 7/34 tumors (21%), with tumors expressing PTEN more likely to respond (n = 6, 35%) than demonstrate SD or PD (n = 1, 6%). An analysis of OS and PFS by biomarker expression revealed that patients with tumors expressing PTEN had significantly longer OS (mean: 23.8 versus 14.3 months, log-rank P = 0.0127) and PFS times (mean: 14.0 versus 6.8 months, log-rank P = 0.035) compared with those with PTEN-negative tumors (Figure 2) . Patients whose tumors expressed VEGF-C tended to have longer survival times (mean: 17.1 versus 12.2 months, log-rank P = 0.0630) than those whose tumors were negative for VEGF-C, although PFS time (mean: 9.9 versus 6.74 months, log-rank P = 0.342) was not markedly different between the groups (Figure 3 ). Strong SMAD4 tumor expression was associated with fewer metastases (P = 0.09, supplementary Table 3 ). Tumor expression of VEGF-D, VEGFR3 and HER2 did not correlate with any of the clinical variables (data not shown).
skin rash
Twenty-eight patients (58%) experienced treatment-related rash of any grade; the median time to the occurrence of rash was 0.6 months (range 0.2-3.0). There was no statistical difference in tumor response (best response, 48% versus 53%) or OS (median 21.7 months versus 18.2 months, log-rank P = 0.625) between patients experiencing rash and those not experiencing rash £2 months (supplementary Table 4 , available at Annals of Oncology online). CT during follow-up was administered to 27 patients (56%) and mainly included platinum plus fluoropyrimidine-based CT in 15 patients; docetaxel with platinum plus CT or irinotecan plus CT in 7 patients each and anthracylines plus platinum plus CT in 6 patients. Small molecule tyrosine kinase inhibitors were administered to three patients and cetuximab to one patient.
discussion
Previous investigations have suggested a potential benefit from cetuximab in combination with CT for patients with GC [16] [17] [18] . Pinto et al. [17] reported a phase II study of 38 patients with locally advanced or metastatic GC treated with cetuximab plus FOLFIRI (FOLCETUX). Nearly 90% of the patients had GC with the remaining 10% having GEC. The reported ORR was 44.1% and the median time to progression (TTP) was 8 months. In the present study, the ORR of 46% was comparable with previously reported findings. In the FOLCETUX study, the main grade 3/4 toxic effects reported were neutropenia (42.1%), acne-like rash (21.1%) and diarrhea (7.9%) [17] . In the present study, within the median treatment duration of 15 weeks, the most prominent grade 3/4 treatment-related toxic effects were diarrhea (15%) and skin reactions (14%). Grade 3/4 skin toxicity, particularly acneiform rash (4%), was low in comparison with other studies in this setting [17, 23] but was similar with that reported in patients with metastatic squamous cell carcinoma of the esophagus treated first line with cetuximab plus cisplatin [24] . This may be due to the use of an in-house reactive skin protocol in many of our centers implemented on the development of exanthema. Furthermore, the absence of treatment-related grade 3/4 hematological AEs and an incidence of <5% of grade 1/2 neutropenia would indicate an advantage for the IF treatment regimen. The IF regimen first described by Moehler et al. [25] provides an additional advantage over FOLFIRI with respect to the administration of the CT since the use of sodium folinate allows parallel i.v. administration thus maintaining the favorable safety profile.
In a recent study by Lordick et al., 52 patients with advanced GC were treated with a combination of cetuximab-and oxaliplatin-based CT. A response rate of 65% was recorded in 46 assessable patients, with a TTP of 7.6 months and an OS of 9.5 months [18] . In a phase II study of 72 patients with GC or GEC treated first-line with cetuximab in combination with cisplatin and docetaxel (the DOCETUX study), an ORR of 41.2%, a median TTP of 5 months and an OS of 9 months were reported [16] . The most common grade 3/4 toxicity was neutropenia that occurred more frequently than in the present study (44.4% versus 6.3%). Recently, data from the ToGA trial in HER2-positive GC and GEC have demonstrated improvement in survival (median survival 13.5 versus 11 months, P = 0.0048, hazard ratio 0.74) and ORR (47.3% versus 34.5%, P = 0.0017) for HER2-selected patients receiving trastuzumab in combination with CT (5-FU or capecitabine) compared with CT alone [12] . While the ORR and the median TTP in these studies are comparable to the results reported here, the survival times are inferior to the median OS of 16.5 months reported in the present study. Collectively, the current efficacy and safety data might support the choice of irinotecan as a backbone for investigations in combination with other types of targeted therapies in this setting.
Accumulating data in mCRC suggests that the selection of patients according to their tumor biomarker status may improve treatment outcomes with EGFR-targeted agents [26] [27] [28] . The biomarkers selected in the present analyses were chosen based on their role in EGFR-mediated signaling or in facilitating tumor proliferation and metastasis. Mutations to KRAS [29, 30] , BRAF [29, 30] and PIK3CA [31] genes and deregulated expression of EGFR [32, 33] , VEGF [21, 32, 33] , PTEN [34] and SMAD4 [35] proteins have been reported in GC. The numbers of patients examined in the biomarker analyses were small. Further the design of the study (nonrandomized and noncontrolled) precluding an accurate assessment of the prognostic or predictive utility of the biomarkers. Therefore, the data should be considered as hypothesis forming; however, some noteworthy associations were found which would require confirmation in larger studies.
Tumor response was more common than nonresponse in patients whose tumors expressed EGFR; however, tumor EGFR expression was not associated with improved PFS or OS. In the FOLCETUX study, EGFR expression was not associated with tumor response although PFS and OS data were not reported [17] . Previous studies have indicated tumor EGFR expression to be associated with poor prognosis in GC patients [36, 37] . However, in a recent study in GC patients treated with cetuximab in combination with FOLFOX those with EGFR tumor expression and low serum ligand levels demonstrated significantly improved response rates compared with the remaining patients [38] . Clearly, data on EGFR expression and clinical outcome in GC patients treated with cetuximab appear contradictory that may reflect the relatively small numbers of patients studied. Further investigations in larger cohorts of patients, perhaps in conjunction with an analysis of tumor and serum EGFR ligand status, are required to elucidate the prognostic and or predictive value of this candidate biomarker in this setting. PTEN tumor expression was found to be associated with longer PFS and survival times than for patients with no tumor PTEN expression. Loss of PTEN expression has been previously associated with resistance to cetuximab in mCRC patients [26] . Our previous findings have suggested that the importance of both the EGFR-and vascular endothelial growth factor receptor (VEGFR)-signaling pathways in the growth and progression of some tumors including GC and that the regulation of these pathways may be closely linked [21] . Preclinical studies have demonstrated that EGFR can upregulate Hif1a leading to the induction of CXCR4 and VEGF ligands expression [39, 40] ; further, cetuximab has been implicated in the downregulation of VEGF ligands in vitro [21, 39] . In the present study, we analyzed for the first time the expression of VEGF-C and VEGF-D ligands and VEGFR3 in patients with GC receiving cetuximab; we found patients with tumors expressing VEGF-C tended to have longer survival times than patients whose tumors were negative for expression. To date, the prognostic value of VEGF and VEGFR expression in GC remains contradictory [21] and requires further investigation before its clinical value can be assessed.
In accordance with previous reports, the frequency of KRAS (9%), BRAF (12%) and PIK3CA (6%) activating mutations were found to be low [29] [30] [31] . Cetuximab in combination with FOLFIRI has previously demonstrated significantly improved efficacy compared with FOLFIRI alone in the first-line treatment of mCRC patients, particularly in those patients with KRAS wild-type tumors [15] . However, unlike in mCRC where KRAS tumor mutation frequencies are 35% [15, 27] , KRAS tumor mutation status may prove to be an unsuitable predictive marker of cetuximab efficacy in GC.
In mCRC patients, associations between the presence and severity of cetuximab-related skin rash with clinical outcome have been reported [41] . In the FOLCETUX study, response rates were higher in patients with grade ‡2 than grade <2 skin rash (53% versus 33%), although this difference was not statistically significant [17] . In the landmark analysis, in the current study, no association between the presence of skin rash £2 months or £1 month with tumor response or OS was found. The role of cetuximab-related skin rash on clinical outcome remains inconclusive in this setting.
In conclusion, this phase II study met its primary objective, and cetuximab plus IF was well tolerated with encouraging additional efficacy data observed. Thus, cetuximab combined with CT in advanced GC and the use of selected biomarkers as predictors of treatment outcome are under further investigation in the ongoing phase III EXPAND trial. 
